The End Brain Cancer Initiative Hosts Free GBM Patient/Caregiver Educational Webinar for Brain Cancer Awareness Month
REDMOND, WA, UNITED STATES, May 8, 2025 / EINPresswire.com / -- Contact: Dellann Elliott Mydland, 425-785-8489, [email protected]
The End Brain Cancer Initiative Hosts Free GBM Patient/Caregiver Educational
Webinar for Brain Cancer Awareness Month
In honor of Brain Cancer Awareness Month, the End Brain Cancer
Initiative (EBCI) is hosting a free educational webinar for patients and caregivers on Friday, May 16,
2025 at 11 AM Pacific Time. The Know All Your Treatment Options (KAYTO) annual online event is
designed specifically for members of the brain tumor, brain cancer, and metastasized brain tumor
community to 'DIRECTLY CONNECT' with top specialists, doctors, and researchers in the field.
Attendees will hear about advanced and FDA approved treatment options, clinical trials, devices,
diagnostics, and more.
The event is free to attend, but pre- registration is required. Registration is open at
endbraincancer.org/know-all-your-treatment-options-2025/. Thank you to presenting sponsors Telix
Pharmaceuticals and Novocure for making this free patient disease educational event possible.
This year's keynote speakers are Dr. John de Groot and Dr. Javier Villanueva-Meyer from the
University of California, San Francisco (UCSF). The doctors will share updates and challenges in the
diagnosis and management of Glioblastoma (GBM), as well as the role for advanced PET imaging and
why it is important to GBM treatment.
About Telix Pharmaceuticals
Telix is a biopharmaceutical company focused on the development and commercialization of
therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is
developing a portfolio of clinical and commercial stage products that aims to address significant unmet
medical needs in oncology and rare diseases. Visit http://www.telixpharma.com/ for further information.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive
forms of cancer through the development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure's commercialized products are approved in certain countries for the
treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural
mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed
clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-
small cell lung cancer and pancreatic cancer. Visit https://www.novocure.com/ for further information.
About the End Brain Cancer Initiative
To support/donate to the End Brain Cancer Initiative's increased access and health delivery for patients,
mission, services and programs, please visit EndBrainCancer.org
The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on
disease education, awareness, outreach, increasing patient access and improving Standard of Care.
The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to
ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain
have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We
believe that IMMEDIATE ACCESS to these options provides this patient community with the best
HOPE for survival and sustained quality of life. We partner with industry, patients, researchers,
advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers
so they can have empowered conversations with their medical teams. Learn more about the End Brain
Cancer Initiative at EndBrainCancer.org.
Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, [email protected]
Dellann Elliott Mydland
End Brain Cancer Initiative
+1 425-785-8489
[email protected]
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix's theranostic candidates. Prostate cancer therapy (TLX591): Oliver Sartor, MD, is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, and led or co-led multiple national and international clinical studies, including four Phase 3 studies pivotal for FDA approval for Bayer, Novartis and Sanofi in advanced prostate cancer. Glioblastoma therapy (TLX101): John de Groot, MD, is an internationally recognized expert in neuro-oncology, spending over 20 years working in the space at MD Anderson Cancer Center, where he led the neuro-oncology clinical research group. He has been at University of California, San Francisco (UCSF) since 2021 where he is a Professor in Residence in the Department of Neurology, and the Chief of the Division of Neuro-Oncology. Dr. de Groot has over 200 peer-reviewed publications and has led or been involved in multiple national and internal clinical studies, as well as involved in key neuro-oncology societal guidelines development from RANO1, and SNO2. Renal cancer imaging (TLX250-CDx, Zircaix®3): Joseph Osborne, MD, Ph.D. is the Chief of Molecular Imaging and Therapeutics and a Professor of Radiology at Weill Cornell Medicine. Dr. Osborne leads the Radioligand Therapy Laboratory at Weill Cornell, which is focused on advancing molecular imaging in alignment with precision medicine. He has also served as principal investigator on an academic-industrial R01 NIH grant to improve access to 68Ga-labeled pharmaceuticals and is the Assistant Director of clinical trial participation at the Meyer Cancer Center. In-person attendance is open to institutional investors and analysts: Advance registration is required for in person attendance. Please RSVP by sending an email to To register for the live webcast: ___________________1 Response Assessment in Neuro-Oncology.2 Society for Neuro-Oncology.3 Brand name subject to final regulatory approval. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). TLX591, TLX101 and TLX250-CDx have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: Lisa Wilson In-Site Communications Email: lwilson@ Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
6 days ago
- Yahoo
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix's theranostic candidates. Prostate cancer therapy (TLX591): Oliver Sartor, MD, is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, and led or co-led multiple national and international clinical studies, including four Phase 3 studies pivotal for FDA approval for Bayer, Novartis and Sanofi in advanced prostate cancer. Glioblastoma therapy (TLX101): John de Groot, MD, is an internationally recognized expert in neuro-oncology, spending over 20 years working in the space at MD Anderson Cancer Center, where he led the neuro-oncology clinical research group. He has been at University of California, San Francisco (UCSF) since 2021 where he is a Professor in Residence in the Department of Neurology, and the Chief of the Division of Neuro-Oncology. Dr. de Groot has over 200 peer-reviewed publications and has led or been involved in multiple national and internal clinical studies, as well as involved in key neuro-oncology societal guidelines development from RANO1, and SNO2. Renal cancer imaging (TLX250-CDx, Zircaix®3): Joseph Osborne, MD, Ph.D. is the Chief of Molecular Imaging and Therapeutics and a Professor of Radiology at Weill Cornell Medicine. Dr. Osborne leads the Radioligand Therapy Laboratory at Weill Cornell, which is focused on advancing molecular imaging in alignment with precision medicine. He has also served as principal investigator on an academic-industrial R01 NIH grant to improve access to 68Ga-labeled pharmaceuticals and is the Assistant Director of clinical trial participation at the Meyer Cancer Center. In-person attendance is open to institutional investors and analysts: Advance registration is required for in person attendance. Please RSVP by sending an email to To register for the live webcast: ___________________1 Response Assessment in Neuro-Oncology.2 Society for Neuro-Oncology.3 Brand name subject to final regulatory approval. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). TLX591, TLX101 and TLX250-CDx have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: Lisa Wilson In-Site Communications Email: lwilson@ Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Yahoo
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting. The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints, including one-year and pain-free survival rates. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group, 68.1%, compared to 60.2% for those who received gemcitabine and nab-paclitaxel alone. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median of 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until patients reported an increase of 20 or more points on a visual scale for pain or until death. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival, or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Price Action: NVCR stock is trading lower by 8.63% to $17.46 at last check Monday. Read Next:Photo by Aunt Spray via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
